Known targets — ChEMBL curated mechanism
ACHESCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9A
The experimentally established mechanism targets of Gluconic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.91 |
| ▸ | PDE4A | P27815 | 1/20 | 0.67 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.52 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.50 |
| ▸ | USP2 | O75604 | 1/20 | 0.50 |
| ▸ | SLCO1B1 | Q9Y6L6 | 1/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.38 |
| ▸ | OR51E2 | Q9H255 | 1/20 | 0.35 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | CA4 | P22748 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Gluconic Acid SCHEMBL9456606 | 1.00 | LMNA (0.91) | LMNAPDE4AL3MBTL1TDP1USP2 | |
| Gluconic Acid SCHEMBL35424 | 1.00 | LMNA (0.91) | LMNAPDE4AL3MBTL1TDP1USP2 | |
| Gluconic Acid SCHEMBL3768836 | 1.00 | LMNA (0.91) | LMNAPDE4AL3MBTL1TDP1USP2 | |
| SCHEMBL1876132 | 0.98 | LMNA (0.87) | LMNAPDE4AL3MBTL1TDP1USP2 | |
| Gluconic Acid SCHEMBL22442432 | 0.98 | LMNA (0.87) | LMNAPDE4AL3MBTL1TDP1USP2 | |
| Gluconic Acid SCHEMBL693435 | 0.98 | LMNA (0.95) | LMNAPDE4AL3MBTL1TDP1USP2 | |
| Gluconic Acid SCHEMBL2540660 | 0.98 | LMNA (0.87) | LMNAPDE4AL3MBTL1TDP1USP2 | |
| Gluconic Acid SCHEMBL809372 | 0.98 | LMNA (0.87) | LMNAPDE4AL3MBTL1TDP1USP2 | |
| Gluconic Acid SCHEMBL7265130 | 0.98 | LMNA (0.87) | LMNAPDE4AL3MBTL1TDP1USP2 | |
| Gluconic Acid SCHEMBL721131 | 0.98 | LMNA (0.87) | LMNAPDE4AL3MBTL1TDP1USP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-1132737-A | Simple prodn process of active ferrous lactate, gluconate and other organic salt | YAO MINGQIN (CN) | 1996-10-09 | — | — | CN | claimed |
| EP-2611438-B1 | DRY POWDER FORMULATIONS AND METHODS FOR TREATING PULMONARY DISEASES | PULMATRIX OPERATING CO INC (US) | 2020-04-01 | — | — | EP | disclosed |
| EP-3470057-A1 | CATIONIC DRY POWDERS COMPRISING MAGNESIUM SALT | Pulmatrix Operating Company, Inc. (US) | 2019-04-17 | — | — | EP | disclosed |
| EP-2621488-B1 | CATIONIC DRY POWDERS | PULMATRIX OPERATING CO INC (US) | 2018-11-07 | — | — | EP | disclosed |
| US-20180153996-A1 | DRY POWDER FORMULATIONS AND METHODS FOR TREATING PULMONARY DISEASES | PULMATRIX OPERATING CO INC (US) | 2018-06-07 | — | — | US | disclosed |
| CN-107693539-A | The medical composition and its use of various trace elements | 刘力 | 2018-02-16 | — | — | CN | disclosed |
| US-9744130-B2 | Cationic dry powders | PULMATRIX OPERATING COMPANY, INC. (US) | 2017-08-29 | — | — | US | disclosed |
| EP-3184099-A1 | DRY POWDER FORMULATIONS AND METHODS FOR TREATING PULMONARY DISEASES | Pulmatrix, Inc. (US) | 2017-06-28 | — | — | EP | disclosed |
| US-20170020813-A1 | CATIONIC DRY POWDERS | PULMATRIX OPERATING COMPANY, INC. (US) | 2017-01-26 | — | — | US | disclosed |
| US-9433576-B2 | Cationic dry powders | PULMATRIX, INC. (US) | 2016-09-06 | — | — | US | disclosed |
| US-9061352-B2 | Dry powder formulations and methods for treating pulmonary diseases | PULMATRIX, INC. (US) | 2015-06-23 | — | — | US | disclosed |
| US-20130243828-A1 | CATIONIC DRY POWDERS | PULMATRIX, INC. (US) | 2013-09-19 | — | — | US | disclosed |
| US-20130213398-A1 | DRY POWDER FORMULATIONS AND METHODS FOR TREATING PULMONARY DISEASES | PULMATRIX OPERATING COMPANY, INC. | 2013-08-22 | — | — | US | disclosed |
| EP-2621488-A1 | CATIONIC DRY POWDERS | Pulmatrix, Inc. (US) | 2013-08-07 | — | — | EP | disclosed |
| EP-2611438-A1 | DRY POWDER FORMULATIONS AND METHODS FOR TREATING PULMONARY DISEASES | Pulmatrix, Inc. (US) | 2013-07-10 | — | — | EP | disclosed |
| WO-2012050945-A1 | CATIONIC DRY POWDERS | PULMATRIX, INC. (US) | 2012-04-19 | — | — | WO | disclosed |
| US-20120064126-A1 | DRY POWDER FORMULATIONS AND METHODS FOR TREATING PULMONARY DISEASES | PULMATRIX, INC. (US) | 2012-03-15 | — | — | US | disclosed |
| WO-2012030664-A1 | DRY POWDER FORMULATIONS AND METHODS FOR TREATING PULMONARY DISEASES | PULMATRIX, INC. (US) | 2012-03-08 | — | — | WO | disclosed |
| EP-2410981-A2 | DRY POWDER FORMULATIONS AND METHODS FOR TREATING PULMONARY DISEASES | Pulmatrix, Inc. (US) | 2012-02-01 | — | — | EP | disclosed |
| WO-2010111680-A2 | DRY POWDER FORMULATIONS AND METHODS FOR TREATING PULMONARY DISEASES | PULMATRIX, INC. (US) | 2010-09-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170020813-A1 | CATIONIC DRY POWDERS | SLC30A5, SLC26A3, EXOSC9 | LMNA 1841/4885PDE4A 4346/4885L3MBTL1 3548/4885 |
| US-20130243828-A1 | CATIONIC DRY POWDERS | CA2, ORAI1, TRPV5 | LMNA 1795/4885PDE4A 3225/4885L3MBTL1 3523/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.